Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys

Psychopharmacology

Volumn 164, Issue 3, 2002, Pages 268-276

  Broadbear, Jillian H ^a,b,d   Winger, Gail ^a,b,d   Rice, Kenner C ^b,c,d   Woods, James H ^a,b,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

ACTH; Antalarmin; Cortisol; CRH antagonist; HPA axis; Macaca mulatta; Schedule controlled responding

Indexed keywords

ANTALARMIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; METHOHEXITAL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DRUG EFFECT; DRUG SELF ADMINISTRATION; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSTRUMENTAL CONDITIONING; INTRAVENOUS CATHETER; MALE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY;

ADRENOCORTICOTROPIC HORMONE; ANESTHETICS, INTRAVENOUS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MACACA MULATTA; MALE; METHOHEXITAL; PYRIMIDINES; PYRROLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; TIME FACTORS;

EID: 0036431734     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1187-y     Document Type: Article

References (19)

1. Bornstein S, Webster E, Torpy D, Richman S, Mitsiades N, Igel M, Lewis D, Rice K, Joost H, Tsokos M, Chrousos G (1998) Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 139:1546-1555
2. Broadbear JH, Winger G, Woods JH (1999a) Cocaine responding in rhesus monkeys: Pharmacological antagonism of the HPA effect. J Pharmacol Exp Ther 290:1347-1355
3. Broadbear JH, Winger G, Woods JH (1999b) Glucocorticoid-reinforced responding in the rhesus monkey. Psychopharmacology 147:46-55
4. Cador M, Ahmed S, Koob G, le Moal M, Stinus L (1992) Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role. Brain Res 597:304-309
5. Chen Y, Mansbach R, Winter S, Brooks E, Collins J, Corman M, Dunaiskis A, Faraci W, Gallaschun R, Schmidt A, Schulz D (1997) Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d']pyrimidine: A centrally active corticotropin-releasing factor1 receptor antagonist. J Med Chem 40:1749-1754
6. Deak T, Nguyen K, Ehrlich A, Watkins L, Spencer R, Maier S, Licinio J, Wong M-L, Chrousos G, Webster E, Gold P (1999) The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140:79-86
7. Goeders NE, Guerin GF (2000) Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 23:577-86
8. Goeders N, McNulty M, Mirkis S, McAllister K (1989) Chlordiazepoxide alters intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 33:859-866
9. 3H]-urocortin. Neuropharmacology 36:1439-1446
10. Griebel G, Perrault G, Sanger D (1998) Characterization of the behavioral profile of the non-peptidic CRH receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 138:55-66
11. Habib K, Weld K, Rice K, Pushkas J, Champoux M, Listwak S, Webster E, Atkinson A, Schulkin J, Contoreggi C, Chrousos G, McCann S, Suomi S, Higley JD, Gold P (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084
12. Lundkvist J, Chai Z, Teheranian R, Hasanvan H, Bartfai T, Jenck F, Widmer U, Moreau J-L (1996) A non-peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur J Pharmacol 309:195-200
13. Mansbach R, Brooks E, Chen Y (1997) Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323:21-26
14. Schulz D, Mansbach R, Sprouse J, Braselton J, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt A, Seeger T, Seymour P, Tingley FT, Winston E, Chen Y, Heym J (1996) CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477-10482
15. Shaham Y, Erb S, Leung S, Buczek Y, Stewart J (1998) CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor 1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psycho-pharmacology 137:184-190
16. Webster E, Lewis D, Torpy D, Zachman E, Rice K, Chrousos G (1996) In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137:5747-5750
17. Winger G (1993) Fixed-ratio and time-out changes on behavior maintained by cocaine or methohexital in rhesus monkeys: 1. Comparison of reinforcing strength. Exp Clin Psychopharmacol 1:142-153
18. Winger G, Palmer R, Woods J (1989) Drug-reinforced responding: Rapid determination of dose-response functions. Drug Alcohol Depend 24:135-142
19. Wong M-L, Webster E, Spokes H, Phu P, Ehrhart-Bornstein M, Borstein S, Park C-S, Rice K, Chrousos G, Licinio J, Gold P (1999) Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci 65:PL 53-58